Substituted 2-oxo-1,4-diazacycloalkanes

US6399599B1 · kind B1 · utility

Assignee

• Novartis AG · CH

Inventors

• Rainer Albert · Basel, CH
• Josef Gottfried Meingassner · Wien, AT
• Sompong Wattanasin · Waltham, US
• Gabriele Weitz-Schmidt · Bad Krozingen, DE
• Karl Welzenbach · Basel, CH
• Ulrich Hommel · Mülheim, DE
• Claus Ehrhardt · Lörrach, DE
• Didier Roche · Écully, FR
• Joerg Kallen · Basel, CH

Key dates

• Filing date: Oct 11, 2000
• Grant date: Jun 4, 2002
• Expiry date: Oct 11, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula I wherein n is 1, 2 or 3; R1 is H, C1-4alkyl, aryl, or aryl-C1-4alkyl; Y is C1-4alkylene, —CO—C1-4alkylene, —CO—C2-5alkenylene, —CO—NH—, —CO—C1-3alkylene-NH—, or —CO—O—; R2 is an aromatic or heteroaromatic residue, each being optionally substituted by CF3, halogen, OH, C1-4alkoxy, amino, mono- or di-C1-4alkyl substituted amino, phenyl, benzyl or C1-4alkyl optionally substituted by amino; R3is the side chain present on the C&agr; of an &agr;-amino acid; R4 is biphenylyl, benzyl, hydroxy-benzyl, &agr;- or &bgr;-naphthyl-methyl, 5,6,7,8-tetrahydro-&bgr;-naphthyl-methyl or indolyl-methyl, each being optionally substituted on the ring by CF3, halogen, OH, C1-4alkoxy, amino, mono- or di-C1-4alkyl substituted amino, phenyl, benzyl or C1-4alkyl optionally substituted by amino; and X is —CN, —NR5R6 or —O—R8 wherein R5 is H, C1-6alkyl, aryl or aryl-C1-4alkyl; R6 is H or C1-6alkyl; and R8 is H, C1-4alkyl, aryl or aryl-C1-4alkyl; in free form or in salt form; which are useful in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1, -ICAM-2 or -ICAM-3 inter…